Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

Completed · Phase 2

Conditions studied: Kidney Diseases

In brief

An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.

Key facts

Study ID

NCT04123613

Run by

DiaMedica Therapeutics Inc

People needed

79

Starts

2019-12-17

Expected to finish

2022-03-16

Last updated by the study team

2022-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cohort I
• African American
• Hypertension as defined by the American Heart Association for Stage I hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension.
• Cohort II
• IgA nephropathy confirmed by medical history with biopsy
• Cohort III
• Diabetes Mellitus (Type 2) with hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension
• Hemoglobin A1c ≥7% at screening
• Both Cohorts
• Participant is willing and able to provide informed consent for study participation
• Participant male or female ≥ 18 years of age
• Participant has CKD as defined by using CKD EPI for Stage II 60 to <90 mL/min/1.73 m2 or Stage III 30 to <60 mL/min/1.73 m2
• UACR >150 mg/g and <5000 mg/g at screening
• Participant is clinically stable with respect to underlying renal impairment as assessed by the Investigator's medical evaluation

You may not qualify if…

• Participant has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 1
• Participant has a current diagnosis and/or is taking medication or diet control for diabetes (cohort I and II only)
• Participant has an A1c > 7% at screening (cohort I and II only)
• Participant received corticosteroid therapy within last 3 months
• Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits
• Participant has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis
• Participant has been previously diagnosed with kidney disease other than for hypertension, IgA or Diabetes Mellitus (Type II)
• Participant has hypotension as defined by systolic blood pressure ≤ 90 mmHg and diastolic blood pressure ≤ 60 mmHg at screen
• ACEi or GLP-1 medication prescribed for and taken by Participant (must not be taking for 5 half-lives prior to study drug administration and for 10 days post study drug administration)
• Participant has a current malignancy or active malignancy ≤ 2 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ 6 months have elapsed since the procedure
• Participant has an active infection at the time of enrollment, and/or a history of clinically significant acute bacterial, viral, or fungal systemic infections that required systemic treatment with a completed therapy in the last 7 days prior to enrollment
• Participant has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency)
• Participant is pregnant or nursing or is planning a pregnancy during the study period
• Participant is male or female of childbearing potential, is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective contraception during the study
• Participant has received any investigational drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration starting on Day 1
• Participant has renal artery stenosis as determined at screen with medical history
• Participant received a kidney transplant
• Participant does not have adequate venous access for blood sampling
• Participant has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results
• Participant has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the Participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
• Participant has any significant arrhythmia or conduction abnormality, which in the opinion of the Investigators and Medical Monitor may interfere with the safety of the Participant

Where it is running

• Aventiv Research — Mesa, Arizona, United States
• Amcis Research Center — Granada Hills, California, United States
• IMD Clinical Trials Inc — Los Angeles, California, United States
• Amicis Reserch Center — Northridge, California, United States
• Innovative Healthcare Institute — Coral Springs, Florida, United States
• Elixia at Florida Kidney Physicians-SE — Fort Lauderdale, Florida, United States
• Pines Clinical Research-Hollywood — Hollywood, Florida, United States
• Elixia at Florida Kidney Physicians — Temple Terrace, Florida, United States
• Boise Kidney & Hypertension Institute — Meridian, Idaho, United States
• Research by Design LLC — Chicago, Illinois, United States
• New Orleans Center for Clinical Research, an AMR Company — New Orleans, Louisiana, United States
• Elixia At Clincal Renal Associates — Upland, Pennsylvania, United States
• Nephrotex Research Group, LLC — Dallas, Texas, United States
• RDRI — DeSoto, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.